Nutriband (Nutriband) Pre-Tax Income : $-5.49 Mil (TTM As of Jan. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nutriband Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Nutriband's pretax income for the three months ended in Jan. 2024 was $-1.88 Mil. Its pretax income for the trailing twelve months (TTM) ended in Jan. 2024 was $-5.49 Mil. Nutriband's pretax margin was -358.29%.

During the past 9 years, Nutriband's highest Pretax Margin was -215.53%. The lowest was -1359.59%. And the median was -372.51%.

Nutriband Pre-Tax Income Historical Data

The historical data trend for Nutriband's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nutriband Pre-Tax Income Chart

Nutriband Annual Data

Trend

Jan16

Jan17

Jan18

Jan19

Jan20

Jan21

Jan22

Jan23

Jan24

Pre-Tax Income

Get a 7-Day Free Trial

-2.72

-2.93

-6.18

-4.48

-5.49

Nutriband Quarterly Data
	Apr19	Jul19	Oct19	Jan20	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24
Pre-Tax Income	Get a 7-Day Free Trial															-1.68	-1.02	-0.83	-1.76	-1.88

Competitive Comparison of Nutriband's Pre-Tax Income

For the Biotechnology subindustry, Nutriband's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nutriband's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nutriband's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Nutriband's Pre-Tax Income falls into.

Nutriband Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Nutriband's Pretax Income for the fiscal year that ended in Jan. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-4.872	+	-0.554	+	-0.076	+	0.017	+	-8.8817841970013E-16
	=	-5.49

Nutriband's Pretax Income for the quarter that ended in Jan. 2024 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-1.306	+	0	+	-0.023	+	0.003	+	-0.555
	=	-1.88

Pre-Tax Income for the trailing twelve months (TTM) ended in Jan. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.49 Mil.

Nutriband (NAS:NTRB) Pre-Tax Income Explanation

Nutriband's Pretax Margin for the quarter that ended in Jan. 2024 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-1.881	/	0.525
	=	-358.29%

During the past 9 years, Nutriband's highest Pretax Margin was -215.53%. The lowest was -1359.59%. And the median was -372.51%.

Nutriband Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Nutriband's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

Nutriband (Nutriband) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nutriband Inc (NAS:NTRB) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

9WV:Germany

Address

121 South Orange Avenue, Suite 1500, Orlando, FL, USA, 32801

Website

https://www.nutriband.com

Nutriband Inc is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's lead product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.

Executives

Michael Davidov	director	60 EAST 42 STREET, NEW YORK NY 10165
Serguei Melnik	director, 10 percent owner, officer: Chief Financial Officer
Gareth Sheridan	director, 10 percent owner, officer: CEO	6064 CENTRAL COLLEGE RD., NEW ALBANY OH 43054
Vitalie Botgros	director, 10 percent owner, officer: Chairman of the BOD	GREGERSTR 36B, FISHAMEND C4 2401